Chong Kun Dang Pharmaceutical (XKRX:185750) Total Liabilities : ₩588,331 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical Total Liabilities?

Chong Kun Dang Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2024 was ₩588,331 Mil.

Chong Kun Dang Pharmaceutical's quarterly Total Liabilities increased from Sep. 2023 (₩539,246.92 Mil) to Dec. 2023 (₩586,793.27 Mil) and increased from Dec. 2023 (₩586,793.27 Mil) to Mar. 2024 (₩588,331.00 Mil).

Chong Kun Dang Pharmaceutical's annual Total Liabilities increased from Dec. 2021 (₩480,890.43 Mil) to Dec. 2022 (₩503,594.00 Mil) and increased from Dec. 2022 (₩503,594.00 Mil) to Dec. 2023 (₩586,793.27 Mil).

Chong Kun Dang Pharmaceutical Total Liabilities Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical Total Liabilities Chart

Chong Kun Dang Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

326,398.91

394,740.34

480,890.43

503,594.00

586,793.27

Chong Kun Dang Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															527,863.46	499,746.86	539,246.92	586,793.27	588,331.00

Chong Kun Dang Pharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Chong Kun Dang Pharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	511465.847	+	(34996.514	+	39307.888
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	1023.018)
	=	586,793

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1402428.436	-	815635.169
	=	586,793

Chong Kun Dang Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	502378.858	+	(41212.786	+	44431.347
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	308.008)
	=	588,331

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1414821.246	-	826490.247
	=	588,331

Chong Kun Dang Pharmaceutical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756

Website

http://chongkundang.en.ec21.com

Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines